nodes	percent_of_prediction	percent_of_DWPC	metapath
Diphenhydramine—CYP2B6—Thiotepa—urinary bladder cancer	0.199	0.322	CbGbCtD
Diphenhydramine—SLC22A2—Cisplatin—urinary bladder cancer	0.106	0.171	CbGbCtD
Diphenhydramine—PTGS1—Etoposide—urinary bladder cancer	0.0708	0.115	CbGbCtD
Diphenhydramine—CYP2B6—Cisplatin—urinary bladder cancer	0.0549	0.0889	CbGbCtD
Diphenhydramine—CYP1A2—Fluorouracil—urinary bladder cancer	0.0379	0.0614	CbGbCtD
Diphenhydramine—CYP2B6—Doxorubicin—urinary bladder cancer	0.0368	0.0596	CbGbCtD
Diphenhydramine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0342	0.0553	CbGbCtD
Diphenhydramine—CYP1A2—Etoposide—urinary bladder cancer	0.0316	0.0512	CbGbCtD
Diphenhydramine—CYP2C9—Cisplatin—urinary bladder cancer	0.029	0.047	CbGbCtD
Diphenhydramine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0178	0.0288	CbGbCtD
Diphenhydramine—CYP2C19—urine—urinary bladder cancer	0.00642	0.0963	CbGeAlD
Diphenhydramine—CYP1A2—urine—urinary bladder cancer	0.00524	0.0786	CbGeAlD
Diphenhydramine—CYP2C9—urine—urinary bladder cancer	0.00498	0.0746	CbGeAlD
Diphenhydramine—CYP2D6—urine—urinary bladder cancer	0.00373	0.056	CbGeAlD
Diphenhydramine—CHRM2—prostate gland—urinary bladder cancer	0.00304	0.0457	CbGeAlD
Diphenhydramine—SLC22A2—renal system—urinary bladder cancer	0.00288	0.0433	CbGeAlD
Diphenhydramine—CYP2C18—vagina—urinary bladder cancer	0.00268	0.0401	CbGeAlD
Diphenhydramine—SLC22A5—prostate gland—urinary bladder cancer	0.00208	0.0312	CbGeAlD
Diphenhydramine—SLC22A1—renal system—urinary bladder cancer	0.00204	0.0306	CbGeAlD
Diphenhydramine—HRH1—prostate gland—urinary bladder cancer	0.00176	0.0264	CbGeAlD
Diphenhydramine—SLC22A5—seminal vesicle—urinary bladder cancer	0.00176	0.0264	CbGeAlD
Diphenhydramine—PTGS1—prostate gland—urinary bladder cancer	0.00163	0.0245	CbGeAlD
Diphenhydramine—Benzphetamine—POR—urinary bladder cancer	0.0016	0.305	CrCbGaD
Diphenhydramine—SLC22A1—vagina—urinary bladder cancer	0.00148	0.0221	CbGeAlD
Diphenhydramine—SLC22A5—renal system—urinary bladder cancer	0.00142	0.0212	CbGeAlD
Diphenhydramine—SLC22A5—urethra—urinary bladder cancer	0.00139	0.0209	CbGeAlD
Diphenhydramine—PTGS1—seminal vesicle—urinary bladder cancer	0.00138	0.0207	CbGeAlD
Diphenhydramine—HRH1—epithelium—urinary bladder cancer	0.00129	0.0194	CbGeAlD
Diphenhydramine—CYP1A2—renal system—urinary bladder cancer	0.00128	0.0192	CbGeAlD
Diphenhydramine—Nausea—Valrubicin—urinary bladder cancer	0.00125	0.00738	CcSEcCtD
Diphenhydramine—Fatigue—Mitomycin—urinary bladder cancer	0.00125	0.00737	CcSEcCtD
Diphenhydramine—HRH1—smooth muscle tissue—urinary bladder cancer	0.00125	0.0187	CbGeAlD
Diphenhydramine—CYP2B6—renal system—urinary bladder cancer	0.00123	0.0184	CbGeAlD
Diphenhydramine—PTGS1—epithelium—urinary bladder cancer	0.0012	0.018	CbGeAlD
Diphenhydramine—Dysuria—Thiotepa—urinary bladder cancer	0.0012	0.00707	CcSEcCtD
Diphenhydramine—Feeling abnormal—Mitomycin—urinary bladder cancer	0.00119	0.00705	CcSEcCtD
Diphenhydramine—HRH1—urethra—urinary bladder cancer	0.00118	0.0177	CbGeAlD
Diphenhydramine—Irritability—Fluorouracil—urinary bladder cancer	0.00117	0.00691	CcSEcCtD
Diphenhydramine—PTGS1—smooth muscle tissue—urinary bladder cancer	0.00115	0.0173	CbGeAlD
Diphenhydramine—CYP2C19—vagina—urinary bladder cancer	0.00114	0.0171	CbGeAlD
Diphenhydramine—SLC22A5—female reproductive system—urinary bladder cancer	0.00113	0.017	CbGeAlD
Diphenhydramine—PTGS1—renal system—urinary bladder cancer	0.00111	0.0167	CbGeAlD
Diphenhydramine—Irritability—Cisplatin—urinary bladder cancer	0.00111	0.00655	CcSEcCtD
Diphenhydramine—Neuritis—Epirubicin—urinary bladder cancer	0.0011	0.0065	CcSEcCtD
Diphenhydramine—Agranulocytosis—Thiotepa—urinary bladder cancer	0.00107	0.00629	CcSEcCtD
Diphenhydramine—Asthenia—Mitomycin—urinary bladder cancer	0.00104	0.00614	CcSEcCtD
Diphenhydramine—SLC22A5—vagina—urinary bladder cancer	0.00103	0.0154	CbGeAlD
Diphenhydramine—Neuritis—Doxorubicin—urinary bladder cancer	0.00102	0.00602	CcSEcCtD
Diphenhydramine—Diarrhoea—Mitomycin—urinary bladder cancer	0.000991	0.00585	CcSEcCtD
Diphenhydramine—CYP2B6—female reproductive system—urinary bladder cancer	0.000984	0.0148	CbGeAlD
Diphenhydramine—Sweating increased—Cisplatin—urinary bladder cancer	0.000978	0.00578	CcSEcCtD
Diphenhydramine—CYP2C9—female reproductive system—urinary bladder cancer	0.000975	0.0146	CbGeAlD
Diphenhydramine—Photosensitivity reaction—Fluorouracil—urinary bladder cancer	0.000967	0.00571	CcSEcCtD
Diphenhydramine—HRH1—female reproductive system—urinary bladder cancer	0.000961	0.0144	CbGeAlD
Diphenhydramine—Dizziness—Mitomycin—urinary bladder cancer	0.000958	0.00566	CcSEcCtD
Diphenhydramine—Tinnitus—Thiotepa—urinary bladder cancer	0.000956	0.00565	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Gemcitabine—urinary bladder cancer	0.000942	0.00556	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Fluorouracil—urinary bladder cancer	0.000926	0.00547	CcSEcCtD
Diphenhydramine—Vomiting—Mitomycin—urinary bladder cancer	0.000921	0.00544	CcSEcCtD
Diphenhydramine—Chills—Thiotepa—urinary bladder cancer	0.00092	0.00543	CcSEcCtD
Diphenhydramine—CYP2D6—renal system—urinary bladder cancer	0.000913	0.0137	CbGeAlD
Diphenhydramine—Rash—Mitomycin—urinary bladder cancer	0.000913	0.00539	CcSEcCtD
Diphenhydramine—Dermatitis—Mitomycin—urinary bladder cancer	0.000912	0.00539	CcSEcCtD
Diphenhydramine—Headache—Mitomycin—urinary bladder cancer	0.000907	0.00536	CcSEcCtD
Diphenhydramine—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.000896	0.00529	CcSEcCtD
Diphenhydramine—Sweating increased—Etoposide—urinary bladder cancer	0.000896	0.00529	CcSEcCtD
Diphenhydramine—CYP2B6—vagina—urinary bladder cancer	0.00089	0.0134	CbGeAlD
Diphenhydramine—PTGS1—female reproductive system—urinary bladder cancer	0.00089	0.0134	CbGeAlD
Diphenhydramine—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.000881	0.00521	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Cisplatin—urinary bladder cancer	0.000878	0.00518	CcSEcCtD
Diphenhydramine—Tension—Thiotepa—urinary bladder cancer	0.000876	0.00517	CcSEcCtD
Diphenhydramine—HRH1—vagina—urinary bladder cancer	0.00087	0.013	CbGeAlD
Diphenhydramine—Nervousness—Thiotepa—urinary bladder cancer	0.000867	0.00512	CcSEcCtD
Diphenhydramine—Nausea—Mitomycin—urinary bladder cancer	0.00086	0.00508	CcSEcCtD
Diphenhydramine—Toremifene—ESR1—urinary bladder cancer	0.000842	0.16	CrCbGaD
Diphenhydramine—Vision blurred—Thiotepa—urinary bladder cancer	0.000841	0.00497	CcSEcCtD
Diphenhydramine—Agitation—Thiotepa—urinary bladder cancer	0.00082	0.00484	CcSEcCtD
Diphenhydramine—PTGS1—vagina—urinary bladder cancer	0.000805	0.0121	CbGeAlD
Diphenhydramine—Neuropathy peripheral—Etoposide—urinary bladder cancer	0.000804	0.00475	CcSEcCtD
Diphenhydramine—Chills—Gemcitabine—urinary bladder cancer	0.000774	0.00457	CcSEcCtD
Diphenhydramine—Convulsion—Thiotepa—urinary bladder cancer	0.000773	0.00457	CcSEcCtD
Diphenhydramine—Agranulocytosis—Etoposide—urinary bladder cancer	0.000765	0.00452	CcSEcCtD
Diphenhydramine—Tinnitus—Cisplatin—urinary bladder cancer	0.000749	0.00443	CcSEcCtD
Diphenhydramine—Confusional state—Thiotepa—urinary bladder cancer	0.000734	0.00434	CcSEcCtD
Diphenhydramine—CYP2D6—female reproductive system—urinary bladder cancer	0.000732	0.011	CbGeAlD
Diphenhydramine—Clomifene—ESR1—urinary bladder cancer	0.000728	0.139	CrCbGaD
Diphenhydramine—Photosensitivity—Methotrexate—urinary bladder cancer	0.000726	0.00429	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000713	0.00421	CcSEcCtD
Diphenhydramine—Tachycardia—Thiotepa—urinary bladder cancer	0.000711	0.0042	CcSEcCtD
Diphenhydramine—Vision blurred—Fluorouracil—urinary bladder cancer	0.000696	0.00411	CcSEcCtD
Diphenhydramine—Anorexia—Thiotepa—urinary bladder cancer	0.000694	0.0041	CcSEcCtD
Diphenhydramine—Photosensitivity—Epirubicin—urinary bladder cancer	0.000679	0.00401	CcSEcCtD
Diphenhydramine—SLC22A5—lymph node—urinary bladder cancer	0.000663	0.00995	CbGeAlD
Diphenhydramine—Chills—Etoposide—urinary bladder cancer	0.000661	0.0039	CcSEcCtD
Diphenhydramine—Vision blurred—Cisplatin—urinary bladder cancer	0.000659	0.00389	CcSEcCtD
Diphenhydramine—Tremor—Cisplatin—urinary bladder cancer	0.000656	0.00387	CcSEcCtD
Diphenhydramine—Paraesthesia—Thiotepa—urinary bladder cancer	0.000654	0.00386	CcSEcCtD
Diphenhydramine—Somnolence—Thiotepa—urinary bladder cancer	0.000647	0.00382	CcSEcCtD
Diphenhydramine—Dyspepsia—Thiotepa—urinary bladder cancer	0.000641	0.00379	CcSEcCtD
Diphenhydramine—Convulsion—Fluorouracil—urinary bladder cancer	0.000639	0.00378	CcSEcCtD
Diphenhydramine—Decreased appetite—Thiotepa—urinary bladder cancer	0.000633	0.00374	CcSEcCtD
Diphenhydramine—Photosensitivity—Doxorubicin—urinary bladder cancer	0.000629	0.00371	CcSEcCtD
Diphenhydramine—Fatigue—Thiotepa—urinary bladder cancer	0.000628	0.00371	CcSEcCtD
Diphenhydramine—Constipation—Thiotepa—urinary bladder cancer	0.000623	0.00368	CcSEcCtD
Diphenhydramine—Irritability—Methotrexate—urinary bladder cancer	0.000608	0.00359	CcSEcCtD
Diphenhydramine—Confusional state—Fluorouracil—urinary bladder cancer	0.000607	0.00359	CcSEcCtD
Diphenhydramine—Convulsion—Cisplatin—urinary bladder cancer	0.000606	0.00358	CcSEcCtD
Diphenhydramine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.0006	0.00354	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.0006	0.00354	CcSEcCtD
Diphenhydramine—Diplopia—Epirubicin—urinary bladder cancer	0.000597	0.00352	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000592	0.0035	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00059	0.00348	CcSEcCtD
Diphenhydramine—Tachycardia—Fluorouracil—urinary bladder cancer	0.000588	0.00347	CcSEcCtD
Diphenhydramine—Anorexia—Gemcitabine—urinary bladder cancer	0.000584	0.00345	CcSEcCtD
Diphenhydramine—Urticaria—Thiotepa—urinary bladder cancer	0.000579	0.00342	CcSEcCtD
Diphenhydramine—Vertigo—Etoposide—urinary bladder cancer	0.000576	0.0034	CcSEcCtD
Diphenhydramine—Anorexia—Fluorouracil—urinary bladder cancer	0.000574	0.00339	CcSEcCtD
Diphenhydramine—Hypotension—Gemcitabine—urinary bladder cancer	0.000572	0.00338	CcSEcCtD
Diphenhydramine—Hypotension—Fluorouracil—urinary bladder cancer	0.000563	0.00332	CcSEcCtD
Diphenhydramine—HRH1—lymph node—urinary bladder cancer	0.000562	0.00844	CbGeAlD
Diphenhydramine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000559	0.0033	CcSEcCtD
Diphenhydramine—Tachycardia—Cisplatin—urinary bladder cancer	0.000557	0.00329	CcSEcCtD
Diphenhydramine—Convulsion—Etoposide—urinary bladder cancer	0.000555	0.00328	CcSEcCtD
Diphenhydramine—Insomnia—Gemcitabine—urinary bladder cancer	0.000554	0.00327	CcSEcCtD
Diphenhydramine—Diplopia—Doxorubicin—urinary bladder cancer	0.000552	0.00326	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000552	0.00326	CcSEcCtD
Diphenhydramine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00055	0.00325	CcSEcCtD
Diphenhydramine—Tamoxifen—ESR2—urinary bladder cancer	0.000546	0.104	CrCbGaD
Diphenhydramine—Insomnia—Fluorouracil—urinary bladder cancer	0.000545	0.00322	CcSEcCtD
Diphenhydramine—Somnolence—Gemcitabine—urinary bladder cancer	0.000545	0.00322	CcSEcCtD
Diphenhydramine—Anorexia—Cisplatin—urinary bladder cancer	0.000544	0.00322	CcSEcCtD
Diphenhydramine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000541	0.00319	CcSEcCtD
Diphenhydramine—Somnolence—Fluorouracil—urinary bladder cancer	0.000535	0.00316	CcSEcCtD
Diphenhydramine—Hypotension—Cisplatin—urinary bladder cancer	0.000534	0.00315	CcSEcCtD
Diphenhydramine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000533	0.00315	CcSEcCtD
Diphenhydramine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00053	0.00313	CcSEcCtD
Diphenhydramine—Fatigue—Gemcitabine—urinary bladder cancer	0.000528	0.00312	CcSEcCtD
Diphenhydramine—Confusional state—Etoposide—urinary bladder cancer	0.000527	0.00312	CcSEcCtD
Diphenhydramine—Constipation—Gemcitabine—urinary bladder cancer	0.000524	0.00309	CcSEcCtD
Diphenhydramine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000524	0.00309	CcSEcCtD
Diphenhydramine—Asthenia—Thiotepa—urinary bladder cancer	0.000523	0.00309	CcSEcCtD
Diphenhydramine—PTGS1—lymph node—urinary bladder cancer	0.000521	0.00781	CbGeAlD
Diphenhydramine—Dysuria—Methotrexate—urinary bladder cancer	0.000515	0.00304	CcSEcCtD
Diphenhydramine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000513	0.00303	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000512	0.00303	CcSEcCtD
Diphenhydramine—Tachycardia—Etoposide—urinary bladder cancer	0.000511	0.00302	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000506	0.00299	CcSEcCtD
Diphenhydramine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000505	0.00298	CcSEcCtD
Diphenhydramine—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000503	0.00297	CcSEcCtD
Diphenhydramine—Anorexia—Etoposide—urinary bladder cancer	0.000499	0.00295	CcSEcCtD
Diphenhydramine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000498	0.00294	CcSEcCtD
Diphenhydramine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000496	0.00293	CcSEcCtD
Diphenhydramine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000496	0.00293	CcSEcCtD
Diphenhydramine—Drowsiness—Methotrexate—urinary bladder cancer	0.000491	0.0029	CcSEcCtD
Diphenhydramine—Hypotension—Etoposide—urinary bladder cancer	0.000489	0.00289	CcSEcCtD
Diphenhydramine—Dysuria—Epirubicin—urinary bladder cancer	0.000482	0.00285	CcSEcCtD
Diphenhydramine—Dizziness—Thiotepa—urinary bladder cancer	0.000482	0.00284	CcSEcCtD
Diphenhydramine—Oxaprozin—PTGS2—urinary bladder cancer	0.00048	0.0914	CrCbGaD
Diphenhydramine—Urticaria—Fluorouracil—urinary bladder cancer	0.000479	0.00283	CcSEcCtD
Diphenhydramine—Pollakiuria—Epirubicin—urinary bladder cancer	0.000476	0.00281	CcSEcCtD
Diphenhydramine—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000471	0.00278	CcSEcCtD
Diphenhydramine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000471	0.00278	CcSEcCtD
Diphenhydramine—Paraesthesia—Etoposide—urinary bladder cancer	0.00047	0.00277	CcSEcCtD
Diphenhydramine—Somnolence—Etoposide—urinary bladder cancer	0.000465	0.00275	CcSEcCtD
Diphenhydramine—Vomiting—Thiotepa—urinary bladder cancer	0.000463	0.00274	CcSEcCtD
Diphenhydramine—Drowsiness—Epirubicin—urinary bladder cancer	0.00046	0.00272	CcSEcCtD
Diphenhydramine—Rash—Thiotepa—urinary bladder cancer	0.000459	0.00271	CcSEcCtD
Diphenhydramine—Dermatitis—Thiotepa—urinary bladder cancer	0.000459	0.00271	CcSEcCtD
Diphenhydramine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000458	0.00271	CcSEcCtD
Diphenhydramine—Headache—Thiotepa—urinary bladder cancer	0.000456	0.00269	CcSEcCtD
Diphenhydramine—Decreased appetite—Etoposide—urinary bladder cancer	0.000455	0.00269	CcSEcCtD
Diphenhydramine—Fatigue—Etoposide—urinary bladder cancer	0.000451	0.00266	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000451	0.00266	CcSEcCtD
Diphenhydramine—Constipation—Etoposide—urinary bladder cancer	0.000447	0.00264	CcSEcCtD
Diphenhydramine—Dysuria—Doxorubicin—urinary bladder cancer	0.000446	0.00264	CcSEcCtD
Diphenhydramine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000441	0.0026	CcSEcCtD
Diphenhydramine—Asthenia—Gemcitabine—urinary bladder cancer	0.00044	0.0026	CcSEcCtD
Diphenhydramine—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000436	0.00257	CcSEcCtD
Diphenhydramine—Nausea—Thiotepa—urinary bladder cancer	0.000433	0.00256	CcSEcCtD
Diphenhydramine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000431	0.00255	CcSEcCtD
Diphenhydramine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000429	0.00253	CcSEcCtD
Diphenhydramine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000425	0.00251	CcSEcCtD
Diphenhydramine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000419	0.00248	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000417	0.00246	CcSEcCtD
Diphenhydramine—Urticaria—Etoposide—urinary bladder cancer	0.000416	0.00245	CcSEcCtD
Diphenhydramine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000412	0.00243	CcSEcCtD
Diphenhydramine—Tinnitus—Methotrexate—urinary bladder cancer	0.000411	0.00243	CcSEcCtD
Diphenhydramine—Asthenia—Cisplatin—urinary bladder cancer	0.00041	0.00242	CcSEcCtD
Diphenhydramine—Dizziness—Fluorouracil—urinary bladder cancer	0.000398	0.00235	CcSEcCtD
Diphenhydramine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000397	0.00235	CcSEcCtD
Diphenhydramine—Fenoprofen—PTGS2—urinary bladder cancer	0.000396	0.0756	CrCbGaD
Diphenhydramine—Chills—Methotrexate—urinary bladder cancer	0.000396	0.00234	CcSEcCtD
Diphenhydramine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000391	0.00231	CcSEcCtD
Diphenhydramine—Vomiting—Gemcitabine—urinary bladder cancer	0.00039	0.0023	CcSEcCtD
Diphenhydramine—Rash—Gemcitabine—urinary bladder cancer	0.000386	0.00228	CcSEcCtD
Diphenhydramine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000386	0.00228	CcSEcCtD
Diphenhydramine—Tinnitus—Epirubicin—urinary bladder cancer	0.000385	0.00227	CcSEcCtD
Diphenhydramine—Headache—Gemcitabine—urinary bladder cancer	0.000384	0.00227	CcSEcCtD
Diphenhydramine—Vomiting—Fluorouracil—urinary bladder cancer	0.000383	0.00226	CcSEcCtD
Diphenhydramine—Rash—Fluorouracil—urinary bladder cancer	0.00038	0.00224	CcSEcCtD
Diphenhydramine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000379	0.00224	CcSEcCtD
Diphenhydramine—Headache—Fluorouracil—urinary bladder cancer	0.000377	0.00223	CcSEcCtD
Diphenhydramine—Asthenia—Etoposide—urinary bladder cancer	0.000375	0.00222	CcSEcCtD
Diphenhydramine—Chills—Epirubicin—urinary bladder cancer	0.00037	0.00219	CcSEcCtD
Diphenhydramine—Nausea—Gemcitabine—urinary bladder cancer	0.000364	0.00215	CcSEcCtD
Diphenhydramine—Vomiting—Cisplatin—urinary bladder cancer	0.000363	0.00214	CcSEcCtD
Diphenhydramine—Vision blurred—Methotrexate—urinary bladder cancer	0.000362	0.00214	CcSEcCtD
Diphenhydramine—Rash—Cisplatin—urinary bladder cancer	0.00036	0.00213	CcSEcCtD
Diphenhydramine—Dermatitis—Cisplatin—urinary bladder cancer	0.00036	0.00212	CcSEcCtD
Diphenhydramine—Diarrhoea—Etoposide—urinary bladder cancer	0.000358	0.00211	CcSEcCtD
Diphenhydramine—Nausea—Fluorouracil—urinary bladder cancer	0.000358	0.00211	CcSEcCtD
Diphenhydramine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000356	0.0021	CcSEcCtD
Diphenhydramine—Tension—Epirubicin—urinary bladder cancer	0.000353	0.00208	CcSEcCtD
Diphenhydramine—Nervousness—Epirubicin—urinary bladder cancer	0.000349	0.00206	CcSEcCtD
Diphenhydramine—Dizziness—Etoposide—urinary bladder cancer	0.000346	0.00204	CcSEcCtD
Diphenhydramine—Vertigo—Methotrexate—urinary bladder cancer	0.000345	0.00204	CcSEcCtD
Diphenhydramine—Chills—Doxorubicin—urinary bladder cancer	0.000343	0.00202	CcSEcCtD
Diphenhydramine—Nausea—Cisplatin—urinary bladder cancer	0.000339	0.002	CcSEcCtD
Diphenhydramine—Vision blurred—Epirubicin—urinary bladder cancer	0.000339	0.002	CcSEcCtD
Diphenhydramine—Tamoxifen—ESR1—urinary bladder cancer	0.000336	0.0641	CrCbGaD
Diphenhydramine—Convulsion—Methotrexate—urinary bladder cancer	0.000333	0.00196	CcSEcCtD
Diphenhydramine—Vomiting—Etoposide—urinary bladder cancer	0.000333	0.00196	CcSEcCtD
Diphenhydramine—Agitation—Epirubicin—urinary bladder cancer	0.00033	0.00195	CcSEcCtD
Diphenhydramine—Rash—Etoposide—urinary bladder cancer	0.00033	0.00195	CcSEcCtD
Diphenhydramine—Dermatitis—Etoposide—urinary bladder cancer	0.00033	0.00195	CcSEcCtD
Diphenhydramine—Headache—Etoposide—urinary bladder cancer	0.000328	0.00194	CcSEcCtD
Diphenhydramine—Tension—Doxorubicin—urinary bladder cancer	0.000326	0.00193	CcSEcCtD
Diphenhydramine—Nervousness—Doxorubicin—urinary bladder cancer	0.000323	0.00191	CcSEcCtD
Diphenhydramine—Vertigo—Epirubicin—urinary bladder cancer	0.000323	0.00191	CcSEcCtD
Diphenhydramine—Palpitations—Epirubicin—urinary bladder cancer	0.000318	0.00188	CcSEcCtD
Diphenhydramine—Phenylbutazone—PTGS2—urinary bladder cancer	0.000317	0.0604	CrCbGaD
Diphenhydramine—Confusional state—Methotrexate—urinary bladder cancer	0.000316	0.00187	CcSEcCtD
Diphenhydramine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000313	0.00185	CcSEcCtD
Diphenhydramine—Convulsion—Epirubicin—urinary bladder cancer	0.000311	0.00184	CcSEcCtD
Diphenhydramine—Nausea—Etoposide—urinary bladder cancer	0.000311	0.00184	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000307	0.00181	CcSEcCtD
Diphenhydramine—Agitation—Doxorubicin—urinary bladder cancer	0.000306	0.0018	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000303	0.00179	CcSEcCtD
Diphenhydramine—Dry mouth—Epirubicin—urinary bladder cancer	0.000299	0.00177	CcSEcCtD
Diphenhydramine—Vertigo—Doxorubicin—urinary bladder cancer	0.000299	0.00176	CcSEcCtD
Diphenhydramine—Anorexia—Methotrexate—urinary bladder cancer	0.000299	0.00176	CcSEcCtD
Diphenhydramine—Confusional state—Epirubicin—urinary bladder cancer	0.000296	0.00175	CcSEcCtD
Diphenhydramine—Palpitations—Doxorubicin—urinary bladder cancer	0.000294	0.00174	CcSEcCtD
Diphenhydramine—Hypotension—Methotrexate—urinary bladder cancer	0.000293	0.00173	CcSEcCtD
Diphenhydramine—Convulsion—Doxorubicin—urinary bladder cancer	0.000288	0.0017	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000287	0.0017	CcSEcCtD
Diphenhydramine—Tachycardia—Epirubicin—urinary bladder cancer	0.000286	0.00169	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000283	0.00167	CcSEcCtD
Diphenhydramine—Insomnia—Methotrexate—urinary bladder cancer	0.000283	0.00167	CcSEcCtD
Diphenhydramine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000281	0.00166	CcSEcCtD
Diphenhydramine—Anorexia—Epirubicin—urinary bladder cancer	0.00028	0.00165	CcSEcCtD
Diphenhydramine—Somnolence—Methotrexate—urinary bladder cancer	0.000279	0.00165	CcSEcCtD
Diphenhydramine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000277	0.00164	CcSEcCtD
Diphenhydramine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000276	0.00163	CcSEcCtD
Diphenhydramine—Hypotension—Epirubicin—urinary bladder cancer	0.000274	0.00162	CcSEcCtD
Diphenhydramine—Confusional state—Doxorubicin—urinary bladder cancer	0.000274	0.00162	CcSEcCtD
Diphenhydramine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000272	0.00161	CcSEcCtD
Diphenhydramine—Fatigue—Methotrexate—urinary bladder cancer	0.00027	0.0016	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000266	0.00157	CcSEcCtD
Diphenhydramine—Insomnia—Epirubicin—urinary bladder cancer	0.000265	0.00157	CcSEcCtD
Diphenhydramine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000265	0.00156	CcSEcCtD
Diphenhydramine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000263	0.00156	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000262	0.00155	CcSEcCtD
Diphenhydramine—Somnolence—Epirubicin—urinary bladder cancer	0.000261	0.00154	CcSEcCtD
Diphenhydramine—Anorexia—Doxorubicin—urinary bladder cancer	0.000259	0.00153	CcSEcCtD
Diphenhydramine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000258	0.00153	CcSEcCtD
Diphenhydramine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000258	0.00152	CcSEcCtD
Diphenhydramine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000255	0.00151	CcSEcCtD
Diphenhydramine—Hypotension—Doxorubicin—urinary bladder cancer	0.000254	0.0015	CcSEcCtD
Diphenhydramine—Fatigue—Epirubicin—urinary bladder cancer	0.000253	0.00149	CcSEcCtD
Diphenhydramine—Constipation—Epirubicin—urinary bladder cancer	0.000251	0.00148	CcSEcCtD
Diphenhydramine—Urticaria—Methotrexate—urinary bladder cancer	0.000249	0.00147	CcSEcCtD
Diphenhydramine—Insomnia—Doxorubicin—urinary bladder cancer	0.000245	0.00145	CcSEcCtD
Diphenhydramine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000244	0.00144	CcSEcCtD
Diphenhydramine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000242	0.00143	CcSEcCtD
Diphenhydramine—Somnolence—Doxorubicin—urinary bladder cancer	0.000241	0.00142	CcSEcCtD
Diphenhydramine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000239	0.00141	CcSEcCtD
Diphenhydramine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000236	0.00139	CcSEcCtD
Diphenhydramine—Fatigue—Doxorubicin—urinary bladder cancer	0.000234	0.00138	CcSEcCtD
Diphenhydramine—Urticaria—Epirubicin—urinary bladder cancer	0.000233	0.00138	CcSEcCtD
Diphenhydramine—Constipation—Doxorubicin—urinary bladder cancer	0.000232	0.00137	CcSEcCtD
Diphenhydramine—Asthenia—Methotrexate—urinary bladder cancer	0.000225	0.00133	CcSEcCtD
Diphenhydramine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000224	0.00132	CcSEcCtD
Diphenhydramine—Urticaria—Doxorubicin—urinary bladder cancer	0.000216	0.00127	CcSEcCtD
Diphenhydramine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000214	0.00127	CcSEcCtD
Diphenhydramine—Asthenia—Epirubicin—urinary bladder cancer	0.00021	0.00124	CcSEcCtD
Diphenhydramine—Dizziness—Methotrexate—urinary bladder cancer	0.000207	0.00122	CcSEcCtD
Diphenhydramine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000201	0.00119	CcSEcCtD
Diphenhydramine—Vomiting—Methotrexate—urinary bladder cancer	0.000199	0.00118	CcSEcCtD
Diphenhydramine—Rash—Methotrexate—urinary bladder cancer	0.000198	0.00117	CcSEcCtD
Diphenhydramine—Dermatitis—Methotrexate—urinary bladder cancer	0.000197	0.00117	CcSEcCtD
Diphenhydramine—Headache—Methotrexate—urinary bladder cancer	0.000196	0.00116	CcSEcCtD
Diphenhydramine—Asthenia—Doxorubicin—urinary bladder cancer	0.000195	0.00115	CcSEcCtD
Diphenhydramine—Dizziness—Epirubicin—urinary bladder cancer	0.000194	0.00115	CcSEcCtD
Diphenhydramine—Vomiting—Epirubicin—urinary bladder cancer	0.000186	0.0011	CcSEcCtD
Diphenhydramine—Nausea—Methotrexate—urinary bladder cancer	0.000186	0.0011	CcSEcCtD
Diphenhydramine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000186	0.0011	CcSEcCtD
Diphenhydramine—Rash—Epirubicin—urinary bladder cancer	0.000185	0.00109	CcSEcCtD
Diphenhydramine—Dermatitis—Epirubicin—urinary bladder cancer	0.000185	0.00109	CcSEcCtD
Diphenhydramine—Headache—Epirubicin—urinary bladder cancer	0.000184	0.00109	CcSEcCtD
Diphenhydramine—Dizziness—Doxorubicin—urinary bladder cancer	0.000179	0.00106	CcSEcCtD
Diphenhydramine—Nausea—Epirubicin—urinary bladder cancer	0.000174	0.00103	CcSEcCtD
Diphenhydramine—Vomiting—Doxorubicin—urinary bladder cancer	0.000173	0.00102	CcSEcCtD
Diphenhydramine—Rash—Doxorubicin—urinary bladder cancer	0.000171	0.00101	CcSEcCtD
Diphenhydramine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000171	0.00101	CcSEcCtD
Diphenhydramine—Headache—Doxorubicin—urinary bladder cancer	0.00017	0.001	CcSEcCtD
Diphenhydramine—Nausea—Doxorubicin—urinary bladder cancer	0.000161	0.000952	CcSEcCtD
Diphenhydramine—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.48e-05	0.000318	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—NAT2—urinary bladder cancer	4.47e-05	0.000318	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	4.41e-05	0.000313	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	4.4e-05	0.000312	CbGpPWpGaD
Diphenhydramine—SLC22A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.39e-05	0.000311	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	4.38e-05	0.000311	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—GSTT1—urinary bladder cancer	4.37e-05	0.00031	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—GPX1—urinary bladder cancer	4.3e-05	0.000306	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	4.3e-05	0.000305	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	4.26e-05	0.000303	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—ERCC2—urinary bladder cancer	4.23e-05	0.0003	CbGpPWpGaD
Diphenhydramine—SLC22A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.09e-05	0.00029	CbGpPWpGaD
Diphenhydramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	4.06e-05	0.000288	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—MTHFR—urinary bladder cancer	3.97e-05	0.000282	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	3.96e-05	0.000281	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR ligand binding—CXCL8—urinary bladder cancer	3.9e-05	0.000277	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—NQO1—urinary bladder cancer	3.89e-05	0.000276	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—RRM2—urinary bladder cancer	3.86e-05	0.000274	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR ligand binding—CXCL8—urinary bladder cancer	3.84e-05	0.000272	CbGpPWpGaD
Diphenhydramine—SLC22A2—Neuronal System—HRAS—urinary bladder cancer	3.8e-05	0.00027	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—NQO1—urinary bladder cancer	3.78e-05	0.000268	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.75e-05	0.000266	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	3.74e-05	0.000265	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—TYMP—urinary bladder cancer	3.74e-05	0.000265	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.67e-05	0.00026	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	3.64e-05	0.000259	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—NQO1—urinary bladder cancer	3.63e-05	0.000258	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.59e-05	0.000255	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—ENO2—urinary bladder cancer	3.58e-05	0.000254	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	3.58e-05	0.000254	CbGpPWpGaD
Diphenhydramine—SLC22A1—Neuronal System—HRAS—urinary bladder cancer	3.54e-05	0.000252	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	3.47e-05	0.000246	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	3.44e-05	0.000244	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.42e-05	0.000243	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—TYMP—urinary bladder cancer	3.41e-05	0.000242	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—NAT2—urinary bladder cancer	3.38e-05	0.00024	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—RBX1—urinary bladder cancer	3.32e-05	0.000235	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.27e-05	0.000232	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—RBX1—urinary bladder cancer	3.26e-05	0.000232	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—GSTP1—urinary bladder cancer	3.25e-05	0.00023	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—PPARG—urinary bladder cancer	3.22e-05	0.000229	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.2e-05	0.000227	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—GSTP1—urinary bladder cancer	3.15e-05	0.000224	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—TSC1—urinary bladder cancer	3.12e-05	0.000221	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	3.11e-05	0.000221	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—CREBBP—urinary bladder cancer	3.09e-05	0.00022	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3.08e-05	0.000219	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—TSC1—urinary bladder cancer	3.07e-05	0.000218	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.05e-05	0.000216	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—GSTP1—urinary bladder cancer	3.03e-05	0.000215	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—TYMS—urinary bladder cancer	3.02e-05	0.000214	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—GSTM1—urinary bladder cancer	2.98e-05	0.000212	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—NCOR1—urinary bladder cancer	2.98e-05	0.000212	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—JAG1—urinary bladder cancer	2.97e-05	0.000211	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—TYMS—urinary bladder cancer	2.93e-05	0.000208	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.92e-05	0.000207	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—JAG1—urinary bladder cancer	2.92e-05	0.000207	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—RRM2—urinary bladder cancer	2.92e-05	0.000207	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—TYMP—urinary bladder cancer	2.91e-05	0.000207	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—NCOR1—urinary bladder cancer	2.9e-05	0.000206	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—GSTM1—urinary bladder cancer	2.9e-05	0.000206	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—NQO1—urinary bladder cancer	2.88e-05	0.000205	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—GPX1—urinary bladder cancer	2.86e-05	0.000203	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—TYMS—urinary bladder cancer	2.81e-05	0.0002	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—ERCC2—urinary bladder cancer	2.81e-05	0.000199	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.8e-05	0.000199	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—NCOR1—urinary bladder cancer	2.78e-05	0.000197	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—GSTM1—urinary bladder cancer	2.78e-05	0.000197	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—GPX1—urinary bladder cancer	2.77e-05	0.000197	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—ERCC2—urinary bladder cancer	2.72e-05	0.000193	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	2.7e-05	0.000192	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—ENO2—urinary bladder cancer	2.7e-05	0.000192	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.69e-05	0.000191	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	2.68e-05	0.000191	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—GPX1—urinary bladder cancer	2.66e-05	0.000189	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.66e-05	0.000189	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—MTHFR—urinary bladder cancer	2.64e-05	0.000187	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—NAT2—urinary bladder cancer	2.63e-05	0.000187	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	2.62e-05	0.000186	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—ERCC2—urinary bladder cancer	2.61e-05	0.000186	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.58e-05	0.000183	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—MTHFR—urinary bladder cancer	2.56e-05	0.000182	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—PTGS2—urinary bladder cancer	2.53e-05	0.00018	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—RHOA—urinary bladder cancer	2.51e-05	0.000178	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	2.49e-05	0.000176	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	2.49e-05	0.000176	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—RHOA—urinary bladder cancer	2.47e-05	0.000175	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.46e-05	0.000175	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.46e-05	0.000175	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—MTHFR—urinary bladder cancer	2.46e-05	0.000174	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.45e-05	0.000174	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	2.41e-05	0.000171	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	2.41e-05	0.000171	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—S100B—urinary bladder cancer	2.4e-05	0.000171	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.39e-05	0.00017	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—S100B—urinary bladder cancer	2.37e-05	0.000168	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.35e-05	0.000167	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—RHOA—urinary bladder cancer	2.28e-05	0.000162	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—RRM2—urinary bladder cancer	2.27e-05	0.000161	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—RHOA—urinary bladder cancer	2.24e-05	0.000159	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—TYMS—urinary bladder cancer	2.24e-05	0.000159	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—PTEN—urinary bladder cancer	2.21e-05	0.000157	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	2.21e-05	0.000157	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	2.21e-05	0.000157	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.2e-05	0.000156	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—NQO1—urinary bladder cancer	2.18e-05	0.000155	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.17e-05	0.000154	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—NCOR1—urinary bladder cancer	2.16e-05	0.000153	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—PPARG—urinary bladder cancer	2.14e-05	0.000152	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—NCOR1—urinary bladder cancer	2.13e-05	0.000151	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—GPX1—urinary bladder cancer	2.12e-05	0.00015	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.11e-05	0.00015	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—EP300—urinary bladder cancer	2.11e-05	0.00015	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	2.11e-05	0.00015	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—ENO2—urinary bladder cancer	2.11e-05	0.00015	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—IL2—urinary bladder cancer	2.11e-05	0.000149	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.09e-05	0.000149	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	2.08e-05	0.000147	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—PPARG—urinary bladder cancer	2.08e-05	0.000147	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—IL2—urinary bladder cancer	2.07e-05	0.000147	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	2.05e-05	0.000146	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	2.04e-05	0.000145	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.01e-05	0.000143	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2e-05	0.000142	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—CXCL8—urinary bladder cancer	2e-05	0.000142	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.99e-05	0.000142	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—PPARG—urinary bladder cancer	1.99e-05	0.000141	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.99e-05	0.000141	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—CXCL8—urinary bladder cancer	1.97e-05	0.00014	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	1.95e-05	0.000139	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.93e-05	0.000137	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	1.91e-05	0.000136	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—IL2—urinary bladder cancer	1.91e-05	0.000136	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—TERT—urinary bladder cancer	1.91e-05	0.000135	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—IL2—urinary bladder cancer	1.88e-05	0.000134	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—TERT—urinary bladder cancer	1.87e-05	0.000133	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.84e-05	0.000131	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.82e-05	0.000129	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.76e-05	0.000125	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—FGFR3—urinary bladder cancer	1.75e-05	0.000124	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—FGFR3—urinary bladder cancer	1.72e-05	0.000122	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—ESR1—urinary bladder cancer	1.7e-05	0.000121	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.7e-05	0.000121	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.69e-05	0.00012	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	1.68e-05	0.000119	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.68e-05	0.000119	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.67e-05	0.000119	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—ESR1—urinary bladder cancer	1.67e-05	0.000119	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.67e-05	0.000119	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.67e-05	0.000119	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.66e-05	0.000118	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.65e-05	0.000117	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—PTGS2—urinary bladder cancer	1.63e-05	0.000116	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.6e-05	0.000114	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.6e-05	0.000114	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—PPARG—urinary bladder cancer	1.58e-05	0.000112	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.57e-05	0.000111	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	1.57e-05	0.000111	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.55e-05	0.00011	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.54e-05	0.000109	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.54e-05	0.000109	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.54e-05	0.000109	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.52e-05	0.000108	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.52e-05	0.000108	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	1.52e-05	0.000108	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	1.49e-05	0.000106	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.48e-05	0.000105	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.47e-05	0.000104	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	1.47e-05	0.000104	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—PTEN—urinary bladder cancer	1.47e-05	0.000104	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—CREBBP—urinary bladder cancer	1.46e-05	0.000104	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	1.46e-05	0.000104	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.46e-05	0.000104	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—IGF1—urinary bladder cancer	1.45e-05	0.000103	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.44e-05	0.000103	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—EGFR—urinary bladder cancer	1.44e-05	0.000102	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.44e-05	0.000102	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.43e-05	0.000102	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—PTEN—urinary bladder cancer	1.42e-05	0.000101	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.42e-05	0.000101	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—EP300—urinary bladder cancer	1.4e-05	9.93e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	1.38e-05	9.81e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.37e-05	9.72e-05	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—PTEN—urinary bladder cancer	1.37e-05	9.71e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—KRAS—urinary bladder cancer	1.36e-05	9.65e-05	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—EP300—urinary bladder cancer	1.36e-05	9.64e-05	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.36e-05	9.64e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	1.35e-05	9.56e-05	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.35e-05	9.55e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—RHOA—urinary bladder cancer	1.32e-05	9.4e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.32e-05	9.34e-05	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—EP300—urinary bladder cancer	1.3e-05	9.26e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.3e-05	9.24e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.3e-05	9.24e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	1.25e-05	8.85e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.25e-05	8.85e-05	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	1.25e-05	8.84e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—ERBB2—urinary bladder cancer	1.23e-05	8.71e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.22e-05	8.68e-05	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.2e-05	8.5e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	1.18e-05	8.39e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	1.17e-05	8.34e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—CXCL8—urinary bladder cancer	1.16e-05	8.26e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—HRAS—urinary bladder cancer	1.16e-05	8.2e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.15e-05	8.16e-05	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.15e-05	8.16e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—IL2—urinary bladder cancer	1.13e-05	8.02e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—IL2—urinary bladder cancer	1.11e-05	7.89e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	1.1e-05	7.82e-05	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.1e-05	7.81e-05	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.09e-05	7.75e-05	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—PTEN—urinary bladder cancer	1.09e-05	7.71e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—CCND1—urinary bladder cancer	1.08e-05	7.69e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	1.07e-05	7.59e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.07e-05	7.56e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	1.06e-05	7.54e-05	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.06e-05	7.51e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—MMP9—urinary bladder cancer	1.05e-05	7.47e-05	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.05e-05	7.44e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.05e-05	7.44e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—PTEN—urinary bladder cancer	1.05e-05	7.42e-05	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—EP300—urinary bladder cancer	1.04e-05	7.36e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—EP300—urinary bladder cancer	1.01e-05	7.19e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—EP300—urinary bladder cancer	9.97e-06	7.08e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—SRC—urinary bladder cancer	9.86e-06	7e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—SRC—urinary bladder cancer	9.7e-06	6.88e-05	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	9.42e-06	6.68e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	9.33e-06	6.62e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	8.96e-06	6.36e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—MYC—urinary bladder cancer	8.83e-06	6.27e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—MYC—urinary bladder cancer	8.69e-06	6.17e-05	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	8.66e-06	6.15e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	8.64e-06	6.13e-05	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	8.59e-06	6.09e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—EGFR—urinary bladder cancer	8.5e-06	6.03e-05	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	8.21e-06	5.83e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	8.16e-06	5.79e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—KRAS—urinary bladder cancer	8.03e-06	5.7e-05	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—EP300—urinary bladder cancer	7.83e-06	5.56e-05	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	7.55e-06	5.36e-05	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	7.49e-06	5.31e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	7.34e-06	5.21e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—TP53—urinary bladder cancer	7.25e-06	5.15e-05	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—EP300—urinary bladder cancer	7.2e-06	5.11e-05	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—EP300—urinary bladder cancer	7.14e-06	5.07e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—TP53—urinary bladder cancer	7.14e-06	5.07e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	6.94e-06	4.92e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—HRAS—urinary bladder cancer	6.83e-06	4.85e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	6.4e-06	4.54e-05	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—EP300—urinary bladder cancer	6.1e-06	4.33e-05	CbGpPWpGaD
